Cachexia and the acute‐phase protein response in inflammation are regulated by interleukin‐6
- 1 August 1993
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 23 (8), 1889-1894
- https://doi.org/10.1002/eji.1830230824
Abstract
Cachexia and the acute-phase response are common manifestations of inflammation and are presumed to be the product of increased synthesis and release of cytokines, including tumor necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6). IL-1 receptor blockade has been previously shown to attenuate the weight loss, anorexia and acute-phase protein responses associated with a turpentine abscess. However, IL-1 receptor blockade was also associated with a reduced plasma IL-6 response, suggesting that the benefit achieved by IL-1 receptor blockade may be mediated by reduced systemic IL-6 production. To gain a better understanding of the role of IL-6 in this model of inflammation, C57BL/6 mice were passively immunized with either a monoclonal anti-IL-6 antibody (20F3), an anti-IL-1 type I receptor monoclonal antibody (35F5), a non-immune rat IgG, or a combined therapy of 35F5 and 20F3, before receiving a sterile turpentine abscess. IL-6 or IL-1 receptor blockade equally spared body weight and food intake. Compared to IL-1 receptor blockade, passive immunization against IL-6 further reduced the hepatic acute-phase protein response, as represented by serum amyloid P and complement 3. Combined blockade of IL-6 and IL-1 receptor did not result in a further sparing of body weights or improvement of food intake. These results confirm that IL-1 contributes to host cachexia and the acute-phase response following a turpentine abscess, but also show that these actions are dependent upon an IL-6 response. We onclude that the influence of IL-1 on cachexia and the acute-phase response is mediated, at least in part, through IL-6 and, thus, IL-6 may play a pivotal role in the cachexia and acute-phase response to inflammation.Keywords
This publication has 16 references indexed in Scilit:
- Protective effect of anti‐interleukin (IL)‐6 antibody against endotoxin, associated with paradoxically increased IL‐6 levelsEuropean Journal of Immunology, 1992
- Evidence for the involvement of interleukin 6 in experimental cancer cachexia.JCI Insight, 1992
- Role of interleukin 6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor.The Journal of Experimental Medicine, 1992
- Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody.The Journal of Experimental Medicine, 1991
- Interleukin 1 receptor blockade attenuates the host inflammatory response.Proceedings of the National Academy of Sciences of the United States of America, 1990
- Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin FeverThe Journal of Infectious Diseases, 1990
- Interleukin 6, the third mediator of acute‐phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 β and tumor necrosis factor‐αEuropean Journal of Immunology, 1988
- Cachectin: Its Impact on Metabolism and Nutritional StatusAnnual Review of Nutrition, 1988
- Induction of rat acute‐phase proteins by interleukin 6 in vivoEuropean Journal of Immunology, 1988
- Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.The Journal of Experimental Medicine, 1988